Safety and efficacy of Jujadokseo-hwan for memory deficit (amnesia) in mild neurocognitive disorder A protocol for randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial

被引:2
|
作者
Jeong, Jin-Hyung [1 ]
Lee, Ji-Yoon [1 ]
Kim, Ju-Yeon [1 ]
Seo, Young-Kyung [1 ]
Kang, Wee-Chang [2 ]
Kang, Hyung-Won [3 ,4 ]
Park, So-Jung [5 ]
Jang, Hye-Kyoung [5 ]
Park, Yang-Chun [5 ]
Jung, In Chul [1 ]
机构
[1] Daejeon Univ, Coll Korean Med, Dept Oriental Neuropsychiat, Daejeon, South Korea
[2] Daejeon Univ, H Liberal Arts Coll, Dept Stat, Daejeon, South Korea
[3] Wonkwang Univ, Sanbon Hosp, Dept Korean Neuropsychiat, Iksan, Gyeonggi Do, South Korea
[4] Wonkwang Univ, Sanbon Hosp, Inam Neurosci Res Ctr, Iksan, Gyeonggi Do, South Korea
[5] Daejeon Univ, Dunsan Korean Med Hosp, Clin Trial Ctr, Daejeon, South Korea
关键词
herbal medicine; Jujadokseo-hwan; memory deficit; mild cognitive impairment; mild neurocognitive disorder; COGNITIVE IMPAIRMENT; KOREAN VERSION;
D O I
10.1097/MD.0000000000019231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Mild neurocognitive disorder (mNCD) is one of the degenerative diseases that results in memory deficit, and can progress to dementia. The effectiveness of drug therapy for mNCD is still debatable, but treatment of this disease has important implications for postponing or preventing dementia. Jujadokseo-hwan (JDH) is a traditional herbal medicine formulation that exhibits improvement in cognitive abilities and neuroprotective effects. In this study, we will evaluate the safety and efficacy of JDH compared to placebo in mNCD patients. Methods and design: This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial. After obtaining informed consent from all participants and performing the screening process, the participants will be equally divided into an experimental group and a control group. Each participant will visit the trial center 7 times during the 12 weeks of intervention. The follow up study will be conducted 12 weeks after the intervention ends. The primary outcome is the variance in Seoul verbal learning test-elderly's version (SVLT-E) score from baseline to 12 weeks. Secondary outcomes include scores/values for the following variables: SVLT-E, Rey complex figure test, Digit span test, Korean-Boston naming test, calculation ability, controlled oral word association test, Korean-color word stroop test, digit symbol coding, Korean-trail making test-elderly's version, Korean version of mini mental state examination for dementia screening, euro-qol-5 dimension, pattern identifications tool for cognitive disorders, Korean version of Montreal cognitive assessment, Korean quality of life-Alzheimer disease, computerized tongue image analysis system, blood pressure pulse analyzer, bioelectrical impedance analyzer, wearable electroencephalogram device, functional near-infrared spectroscopy system, and cost analysis. Discussion: This is the first trial evaluating the efficacy of JDH for mNCD. We expect this trial will provide strong support for wide use of JDH for mNCD and lead to further research on herbal medicine treatments for mNCD.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial
    Sha, Zhongwei
    Hou, Yiping
    Xue, Chunchun
    Li, Ou
    Li, Zhimin
    Wang, Huiru
    Zhang, Wenjing
    Xu, Jian
    TRIALS, 2020, 21 (01)
  • [2] The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial
    Zhongwei Sha
    Yiping Hou
    Chunchun Xue
    Ou Li
    Zhimin Li
    Huiru Wang
    Wenjing Zhang
    Jian Xu
    Trials, 21
  • [3] Multicenter, randomized, double-blind, placebo-controlled, parallel trial comparing the safety and efficacy of rufinamide
    Biton, V
    Rosenfeld, W
    Schachter, S
    Perdomo, C
    Arroyo, S
    ANNALS OF NEUROLOGY, 2005, 58 : S114 - S114
  • [4] A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS
    Montalban, Xavier
    Hemmer, Bernhard
    Rammohan, Kottil W.
    Giovannoni, Gavin
    De Seze, Jerome
    Bar-Or, Amit
    Arnold, Douglas L.
    Sauter, Annette
    Masterman, Donna
    Fontoura, Paulo
    Chin, Peter
    Garren, Hideki
    Wolinsky, Jerry S.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 17 - 17
  • [5] Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients
    Sakai, Fumihiko
    Suzuki, Norihiro
    Kim, Byung-Kun
    Tatsuoka, Yoshihisa
    Imai, Noboru
    Ning, Xiaoping
    Ishida, Miki
    Nagano, Kaori
    Iba, Katsuhiro
    Kondo, Hiroyuki
    Koga, Nobuyuki
    HEADACHE, 2021, 61 (07): : 1102 - 1111
  • [6] Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients
    Sakai, Fumihiko
    Suzuki, Norihiro
    Kim, Byung-Kun
    Igarashi, Hisaka
    Hirata, Koichi
    Takeshima, Takao
    Ning, Xiaoping
    Shima, Tomoko
    Ishida, Miki
    Iba, Katsuhiro
    Kondo, Hiroyuki
    Koga, Nobuyuki
    HEADACHE, 2021, 61 (07): : 1092 - 1101
  • [7] The Efficacy and Safety of Wenxin Keli in Patients with Frequent Premature Ventricular Contractions: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial
    Hua, Wei
    Gao, Run-Lin
    Zhao, Bu-Chang
    Wang, Jing
    Chen, Xu-Hua
    Cai, Chi
    Zhang, Shu
    CHINESE MEDICAL JOURNAL, 2015, 128 (19) : 2557 - 2564
  • [8] The Efficacy and Safety of Wenxin Keli in Patients with Frequent Premature Ventricular Contractions: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial
    Hua Wei
    Gao Run-Lin
    Zhao Bu-Chang
    Wang Jing
    Chen Xu-Hua
    Cai Chi
    Zhang Shu
    中华医学杂志英文版, 2015, 128 (19) : 2557 - 2564
  • [9] Efficacy of Zhengtian Pill for migraine prophylaxis: A randomized, multicenter, double-blind, placebo-controlled, parallel-group study
    Cao, Kegang
    Yu, Lihua
    Gao, Ying
    Fan, Yongping
    Zhao, Jianjun
    Zhang, Xuezhi
    Xie, Wei
    Yang, Wenming
    Dong, Mengjiu
    Li, Tao
    Qiao, Xiangyang
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2014, 6 (03) : 259 - 267
  • [10] Efficacy and Safety of Dichlorphenamide for the Treatment of Periodic Paralysis: a Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
    Burge, James
    Sansone, Valeria
    McDermott, Michael
    Smith, Patty
    Herr, Barbara
    Tawil, Alrabi
    Pandya, Shree
    Kissel, John
    Ciafaloni, Emma
    Shieh, Perry
    Ralph, Jeffrey
    Amato, Anthony
    Cannon, Stephen
    Trivedi, Jaya
    Barohn, Richard
    Crum, Brian
    Mitsumoto, Hiroshi
    Pestronk, Alan
    Meola, Giovanni
    Conwit, Robin
    Jasek, Mark
    Hanna, Michael
    Griggs, Robert
    NEUROLOGY, 2016, 86